Hypolipidemia is associated with the severity of COVID-19.
COVID-19
Cholesterol
HDL-c
LDL-c
SARS-COV-2
Journal
Journal of clinical lipidology
ISSN: 1933-2874
Titre abrégé: J Clin Lipidol
Pays: United States
ID NLM: 101300157
Informations de publication
Date de publication:
Historique:
received:
01
04
2020
revised:
20
04
2020
accepted:
22
04
2020
pubmed:
21
5
2020
medline:
26
6
2020
entrez:
21
5
2020
Statut:
ppublish
Résumé
Many patients with coronavirus disease 2019 (COVID-19) suffer multiple organ dysfunctions. However, whether patients develop dyslipidemia is unknown. In this study, we aimed to investigate the pathological alterations of low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), and total cholesterol (TC) in COVID-19 patients and their relationships with the disease severity. A retrospective study was performed to examine serum levels of LDL-c, HDL-c, and TC on 597 COVID-19 patients (mild: 394; severe, 171; critical: 32) who were hospitalized in our center between February 1 and March 3, 2020. Age- and gender-matched normal subjects (n = 50) who had routine laboratory lipid tests between October 1 and November 1, 2019 in our center were included as the control group. LDL-c and TC levels were significantly lower in COVID-19 patients as compared with normal subjects (P < .001). There were significant and gradual decreases in levels of LDL-c (median (IQR) in mg/dL, mild: 91 (76, 104); severe: 86 (69, 102); critical: 69 (48, 81); P < .02) and TC (mild: 173 (148, 203); severe: 167 (138, 197); critical: 125 (95, 162); P < .05) across all three groups. HDL-c levels only decreased significantly in critical cases as compared with levels in mild and severe cases. LDL-c and TC levels inversely correlated with C-reactive protein and interleukin-6, and positively correlated with the number of lymphocytes in patients. Development of hypolipidemia begins in patients with mild symptoms. It progressively becomes worse in an association with the disease severity.
Sections du résumé
BACKGROUND
Many patients with coronavirus disease 2019 (COVID-19) suffer multiple organ dysfunctions. However, whether patients develop dyslipidemia is unknown.
OBJECTIVE
In this study, we aimed to investigate the pathological alterations of low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), and total cholesterol (TC) in COVID-19 patients and their relationships with the disease severity.
METHODS
A retrospective study was performed to examine serum levels of LDL-c, HDL-c, and TC on 597 COVID-19 patients (mild: 394; severe, 171; critical: 32) who were hospitalized in our center between February 1 and March 3, 2020. Age- and gender-matched normal subjects (n = 50) who had routine laboratory lipid tests between October 1 and November 1, 2019 in our center were included as the control group.
RESULTS
LDL-c and TC levels were significantly lower in COVID-19 patients as compared with normal subjects (P < .001). There were significant and gradual decreases in levels of LDL-c (median (IQR) in mg/dL, mild: 91 (76, 104); severe: 86 (69, 102); critical: 69 (48, 81); P < .02) and TC (mild: 173 (148, 203); severe: 167 (138, 197); critical: 125 (95, 162); P < .05) across all three groups. HDL-c levels only decreased significantly in critical cases as compared with levels in mild and severe cases. LDL-c and TC levels inversely correlated with C-reactive protein and interleukin-6, and positively correlated with the number of lymphocytes in patients.
CONCLUSIONS
Development of hypolipidemia begins in patients with mild symptoms. It progressively becomes worse in an association with the disease severity.
Identifiants
pubmed: 32430154
pii: S1933-2874(20)30078-7
doi: 10.1016/j.jacl.2020.04.008
pmc: PMC7192140
pii:
doi:
Substances chimiques
Cholesterol, HDL
0
Cholesterol, LDL
0
Cholesterol
97C5T2UQ7J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
297-304Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 National Lipid Association. Published by Elsevier Inc. All rights reserved.
Références
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
J Med Virol. 2020 Jun;92(6):595-601
pubmed: 32100877
Stroke. 1999 Mar;30(3):537-41
pubmed: 10066848
Ann Intern Med. 1972 Oct;77(4):507-13
pubmed: 4642731
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2004 Nov;16(11):664-6
pubmed: 15535901
Lancet Infect Dis. 2020 Apr;20(4):425-434
pubmed: 32105637
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
Int J Infect Dis. 2020 Mar;92:214-217
pubmed: 32007643
Sci Rep. 2017 Aug 22;7(1):9110
pubmed: 28831119
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Sci China Life Sci. 2020 Mar;63(3):457-460
pubmed: 32009228
J Med Virol. 2020 Apr;92(4):441-447
pubmed: 31994742
Clin Lab. 2019 Dec 1;65(12):
pubmed: 31850701
Zhonghua Bing Li Xue Za Zhi. 2005 Oct;34(10):656-60
pubmed: 16536279
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Mod Pathol. 2005 Jan;18(1):1-10
pubmed: 15272286
Lancet. 2003 Jul 26;362(9380):263-70
pubmed: 12892955
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Atherosclerosis. 2008 Jul;199(1):79-86
pubmed: 18054941
Curr HIV/AIDS Rep. 2016 Aug;13(4):218-25
pubmed: 27245605
Chest. 2002 Jun;121(6):1916-20
pubmed: 12065357
Rev Med Virol. 2019 Sep;29(5):e2056
pubmed: 31172625
JAMA. 2020 Feb 24;:
pubmed: 32091533
J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):154-60
pubmed: 25647528
Presse Med. 1991 Nov 23;20(39):1935-8
pubmed: 1837087
J Thorac Oncol. 2020 May;15(5):700-704
pubmed: 32114094
Libyan J Med. 2008 Jun 01;3(2):84-90
pubmed: 21499464
J Infect Dis. 2010 Jan 15;201(2):285-92
pubmed: 19954384
Metabolism. 2020 Jun;107:154243
pubmed: 32320740